BRIUMVI® (ublituximab-xiiy) is a groundbreaking B-cell therapy specifically designed for individuals with relapsing multiple sclerosis (RMS). Uniquely administered as an infusion taking just one hour, BRIUMVI requires only two treatments per year after an initial dose. This innovative approach significantly reduces the burden of daily medication.

BRIUMVI has been clinically proven to reduce the frequency of relapses and the presence of active lesions in patients, offering hope and improved quality of life. Patient support services are available, ensuring users have access to comprehensive information and assistance. Additionally, financial aid options are provided to help manage treatment costs.

Safety is paramount, and BRIUMVI is carefully monitored during infusions to mitigate potential side effects, including infusion reactions and infections. BRIUMVI is indicated for various RMS forms in adults, and healthcare professionals guide patients through the treatment journey, ensuring they remain informed and secure. For those looking for effective RMS management, BRIUMVI offers a promising solution.